A retrospective evaluation of vitamin K1 therapy to reverse the anticoagulant effect of warfarin

Pharmacotherapy

Volumn 23, Issue 10 II, 2003, Pages 1245-1250

  Fan, Jingyang ^a   Armitstead, John A ^a   Adams, Aimee G ^a   Davis, George A ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; VITAMIN K GROUP; WARFARIN;

ADULT; ANTICOAGULATION; BLEEDING; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; REVIEW; TREATMENT INDICATION;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ANTAGONISM; DRUG UTILIZATION REVIEW; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VITAMIN K 1; WARFARIN;

EID: 0141865646     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.12.1245.32701     Document Type: Review

References (25)

1. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(suppl):8S-21.
2. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989;87:153-9.
3. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993;95:315-28.
4. Hylek EM, Chang YC, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160:1612-17.
5. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy Chest 2001;119(suppl):22S-38.
6. Hirsh J, Dalen J, Guyatt G; American College of Chest Physicians. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest 2001;119(1 suppl):1S-2.
7. Wilson SE, Douketis JD, Crowther MA. Treatment of warfarin-associated coagulopathy: a physician survey. Chest 2001;120:1972-6.
8. Libby EN, Garcia DA. A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med 2002;162(16):1893-6.
9. Murphey LM, Byrd DC. Phytonadione education program in a community hospital. Hosp Pharm 2003;38(5):458-62.
10. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study Ann Intern Med 1993;118:511-20.
11. White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995;122:40-2.
12. Crowther MA, Donovan D, Harrison L, et al. Low dose oral vitamin K reliably reverses over anticoagulation due to warfarin. Thromb Haemost 1998;79:1116-18.
13. Watson HG, Baglin T, Laidlaw SL, et al. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001;115:145-9.
14. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomized controlled trial. Lancet 2000;356:1551-3.
15. Patel RJ, Witt DM, Saseen JJ, et al. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000;20(10):1159-66.
16. 1 while continuing warfarin therapy unchanged. Chest 1998;114:1546-50.
17. 1. Ann Intern Med 1997;126(12):959-62.
18. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: a randomized, controlled trial. Ann Intern Med 2002;137(4):251-4.
19. 1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc 2001;76:260-6.
20. Bosse GM, Mallory MD. The safety of intravenously administered vitamin K. Vet Human Toxicol 2002;44(3):174-6.
21. 1. Thromb Haemost 1992;67:13-15.
22. Nee R, Doppenschmidt D, Donovan DJ, et al. Intravenous versus subcutaneous vitamin K in reversing excessive oral anticoagulatton. Am J Cardiol 1999;83:286-8, A6-7.
23. Byrd DC, Stephens MA, Hamann GL, et al. Subcutaneous phytonadione for reversal of warfarin-induced elevation of the international normalized ratio. Am J Health-Syst Pharm 1999;56:2312-15.
24. Whitling AM, Bussey HI, Lyon RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 1998;158:2136-40.
25. Raj G, Kumar R, McKinney P. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999;159: 2721-4.